Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardinal spin-off?

This article was originally published in The Gray Sheet

Executive Summary

Cardinal Health is weighing the possibility of spinning off its $5.6 billion clinical and medical products business as a separate, publicly traded company, the firm said Aug. 7. Last month, Cardinal consolidated its two major business activities of health care product sales and its $80 billion distributor operation into two distinct business units and cut 600 jobs (1"The Gray Sheet" July 21, 2008, In Brief). The clinical and medical products business includes Alaris infusion pumps, Avea respirators, Pyxis medication dispensing system, surgical gowns and gloves

You may also be interested in...



Cardinal Health completes CareFusion spinoff

Healthcare supply chain services firm Cardinal Health completes the planned spinoff of its clinical and medical products business Sept. 1 through a pro rata distribution of 81% of CareFusion stock to Cardinal Health shareholders. Cardinal Health plans to divest its remaining 19% stake in CareFusion within five years. Representing roughly $4.5 billion in annual sales, CareFusion includes Alaris infusion pumps, Avea respirators, Pyxis medication dispensing systems, MedMined electronic infection surveillance services, and ChloraPrep skin preparation products. Spinoff of the San Diego business has been in the works since summer 2008 (1"The Gray Sheet" Aug. 11, 2008)

CareFusion’s spin-off from Cardinal Health set for mid-year

Cardinal Health will spin off its clinical and medical products businesses - representing $4 billion in annual sales - by mid-year, according to the company. Given the name "CareFusion" on Feb. 16, the spin-off entity will include Alaris infusion pumps, Avea respirators, Pyxis medication dispensing systems, the MedMined electronic infection surveillance service, and ChloraPrep skin preparation products. The new firm will be based in San Diego, have 13,000 employes, and is expected to trade on the New York Stock Exchange under the symbol "CFN." The spin-off has been in the works since last summer (1"The Gray Sheet" Aug. 11, 2008, In Brief)

Cardinal Health restructures

Dublin, Ohio-based firm is consolidating into two core businesses and cutting 600 jobs. The new organization, announced July 8, will consist of a Healthcare Supply Chain Services segment, which as a pharmaceutical/medical product distributor generates annual sales of over $80 billion, and a Clinical and Medical Products segment, with annual revenue of $5 billion. The latter group will include Cardinal Health's Alaris infusion pumps, Avea respirators, Pyxis medication dispensing systems, surgical gowns, gloves and other medical products. The firm says that over the next year it will evaluate the fit of a third business group, which includes its Tecomet orthopedic implant manufacturing services unit and Medsystems enteral devices and airway management products. The cost of the restructuring is estimated at $63 million in fiscal year 2009, which began July 1

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026427

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel